Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Trial details
- Registry ID
- NCT05184335
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as RP5063
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety and Efficacy of Brilaroxazine (RP5063) in SchizophreniaNCT05184335 | Reviva Pharmaceuticals | Phase 3 | Recruiting | 2025-02Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |